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1. Introduction 
Wegener’s granulomatosis (WG) is a rare multisystemic autoimmune disease of unknown 
aetiology, characterized by necrotizing granulomatous inflammatory and pauci-immune 
vasculitis in small- and medium-sized blood vessels (capillaries, venules, arterioles and 
arteries) associated with antineutrophil cytoplasmic antibodies (ANCAS) directed against 
proteinase 3 (PR3), a neutrophil serine protease, presented in primary azurophil granules of 
polymorphonuclear neutrophils (PMN) and lysosomes of monocytes. It typically produces 
granulomatous inflammation of the upper and lower respiratory tracts, and a segmental 
necrotizing glomerulonephritis (classic triad of disease), although any organ can be 
involved. 
2. History and epidemiology 
In 1897, Peter McBride described the first patient with this condition. Later, in 1931, Klinger 
(1) reported a case of this disease, a 70-year-old physician with constitutional symptoms, 
inflammation of the upper respiratory tract leading to saddle nose deformity, 
glomerulonephritis and pulmonary lesions. In 1936, the German pathologist, Friedrich 
Wegener (2) published three cases with similar clinical features. Goodman and Churg, in 
1954, described a triad of pathological features of the disease: 1) systemic necrotizing 
angiitis, 2) necrotizing granulomatous inflammation of the respiratory tract, and 3) 
necrotizing glomerulonephritis. 
WG is an uncommon disease with an estimated prevalence, in the United States, of 3 per 
100,000 (3). The incidence and prevalence of WG in the United Kingdom is estimated at 10,2 
cases and 250 cases per million population, respectively. It is extremely rare in blacks 
compared with whites; the male-to-female ratio is 1:1 and, although the disease can be seen 
at any age, the mean age of diagnosis is 40 years (3, 4). 
3. Pathology and pathogenesis 
The histopathologic characteristics of WG are necrotizing vasculitis of small- and medium-
sized blood vessels with granuloma formation, with an important triad of granulomatous 
inflammation, vasculitis and necrosis.  
Lung biopsy shows the typical necrotizing granulomatous vasculitis, almost always with 
multiple and bilateral nodules (50% are cavitated) or diffuse infiltrates, composed of 
neutrophils, lymphocytes, plasma cells, histiocytes and eosinophils.  
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Upper respiratory tract tissue reveals acute and chronic inflammation, necrosis and 
granulomatous lesions, with or without vasculitis (4), being the triad of pathological features 
present in only about 15% of cases. 
Renal involvement is manifested by segmental and focal necrotizing glomerulonephritis, 
often with crescents and mononuclear tubulointerstitial infiltrates, without evidence of 
immune complex deposition (pauci-immune on immunofluorescence or electron 
microscopy). However granulomas are infrequently found in renal biopsy specimens (5).  
The immunopathogenesis of this disease is still unclear, although the knowledge has 
suffered substantial progress in recent years, with both cellular and humoral immunity 
thought to be involved. Also, genetic background and environmental factors may play an 
important role in WG.   
Autoimmune responses to PR3 (Wegener autoantigen) plays a central role in disease 
development, according to in vitro and in vivo experimental data (6). Activated PMNs 
release PR3, which interacts with dendritic cells and induces their maturation into antigen-
presenting cells, able to induce an unbalanced Th1 response, and leading to granuloma 
formation (7). Nowadays, the latter is accepted to be the place of ANCA production, essential 
to the onset of vasculitis, since PR3-ANCA activates PMNs and monocytes to develop a 
respiratory burst, adhere and migrate across the endothelium.  The activated PMN and 
monocytes release pro-inflammatory mediators, such as TNF-α, IL-1, IL-8 (8). This process is 
reinforced by activation of the alternative complement pathway (6). The presence of ANCAs 
suggests the role of humoral autoimmunity (Figure 1). 
 
 
Fig. 1. Pathogenesis of WG. PMN: polymorphonuclear DC: Dentric cell; APC: Antigen-
presenting cell 
It is common to see WG progressing from a localized stage, restricted to the respiratory tract, 
to a systemic disease (generalized), and this transition may be influenced by a number of 
genetic risk factors. There is evidence that the human leukocyte antigen (HLA) system is 
involved both in WG development (9, 10), and other ANCA-positive vasculitides. Research is 
being carried out to confirm this association, for instance, to confirm the possible relation 
between WG and a region on chromosome 6p21.3 (11), although further investigation is needed. 
Indeed, this autoimmune disease is genetically associated with the class II region of the major 
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histocompatibility complex (MHC), such as HLA-DPB1*0401 allele (12, 13). Similarly to other 
autoimmune diseases, the functional polymorphism, 620W, in the intracellular tyrosine 
phosphatase gene PTPN 22, is a predisposing factor for WG in the presence of ANCA. This is 
due to loss of function of the PTPN 22 protein, which is important in T-cell receptor (TCR) 
signaling, via inhibition of key molecules in the receptor pathway, resulting in activation and 
proliferation of T cells and, subsequently, in humoral alterations (14). Another genetic risk 
factor for WG is the CTLA-4 (cytotoxic T-lymphocyte antigen 4) polymorphism (15). 
Environmental exposure to solvents or silica, farming and living in northern latitudes has 
been associated to the development of this autoimmune disease (16).  
The relationship between WG and infectious diseases was first described by Friedrich 
Wegener in 1936 in its original descriptions, when he proposed that infectious agents are 
implicated in the disease pathogenesis (17). Chronic nasal carriage of Staphylococcus aureus 
(the frequency in a healthy population varies from 20-35%) has been associated with a 
higher relapse rate of WG, suggesting a role of these bacteria in its pathophysiology (18). 
Several toxins of this pathogen stimulate B-cell and probably T-cell activity. Also, direct 
stimulation of neutrophils in vitro has been documented (19), with Staphylococcus aureus 
producing proteinases with activity against human proteinase inhibitors, like α1-
antiprotease, which is the main inhibitor of proteinase-3, resulting in persistent 
inflammatory activity (20). Additionally, several reports have noted that antibiotic therapy 
with sulfamethoxazole-trimethoprim has been beneficial in the treatment of refractory or 
limited WG localized to the respiratory tract (21). 
4. Clinical manifestations 
WG has a spectrum of clinical presentations. While the disease is active, most patients have 
nonspecific symptoms and signs such as malaise, weakness, migratory arthralgias, anorexia, 
weight loss, night sweats and fever. It is important to exclude secondary infection when 
fever is present. These constitutional symptoms may last for weeks to months without 
evidence of specific organ involvement. 
Ear, nose and throat (ENT) manifestations are frequent in WG (22). Involvement of the upper 
airways occurs in 95% of the patients, being chronic sinusitis the most common initial 
complaint (67%). Other frequent manifestations include saddle nose deformity by collapse 
of nasal support with bone and cartilage destruction, subglottic tracheal stenosis (16%) 
causing stridor, rhinitis, epistaxis, oral and/or nasal ulcers, serous otitis media, otorrhea and 
hearing loss (conductive and neurosensorial) (23). 
Lung involvement is also common and may be manifested as asymptomatic diffuse 
pulmonary infiltrates (71%), nodules, atelectasis, consolidation and/or pleural effusion or 
may be clinically expressed as cough (34%), hemoptysis (18%) due to bronchiectasis, 
cavitated pulmonary parenchymal lesions or diffuse alveolar hemorrhage (DAH), dyspnoea 
(7%), pleuritic pain and chest discomfort (8%) (24). The development of pulmonary fibrosis 
and pulmonary arterial hypertension may also occur. Chest radiography and computerized 
tomography (CT) scan are important investigations that must be included in the workup of 
these patients. 
WG can also be recognized as tumor-like masses outside the lung, being the breast and 
kidney the most common extra-thoracic locations, although such cases are rare (25). 
Another typical complication is renal disease, which is present in 17% at initial diagnosis 
and in 77% throughout the course of the disease,  manifesting itself with acute renal failure, 
hematuria, red blood cell casts and proteinuria. 
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Eye involvement (52%) is manifested as conjunctivitis, dacryocystitis, keratitis, uveitis, 
scleritis, optic nerve vasculitis, retinal artery occlusion, diplopia and proptosis caused by 
retroorbital mass (26). 
Cutaneous manifestations, present in 45% of patients, are nonspecific findings and usually 
affect the lower extremities. Palpable purpura, papules, subcutaneous nodules, ulcerations, 
livedo reticularis and urticaria are frequent, being leukocytoclastic angiitis (purpura, focal 
necrosis and ulceration) the most common skin lesion (27). 
Musculoskeletal system is also often involved by the vasculitic process, with myalgias, 
polyarticular and symmetric arthralgias, and non-deforming arthritis of the large joints, 
being present in 32% of patients at initial diagnosis and in 67% throughout the course of the 
disease. 
Cerebral manifestations (23%) include cranial nerve neuropathy, cerebral vasculitis, 
mononeuritis multiplex, pachymeningitis, central nervous system mass lesions, among 
other less frequent manifestations. Peripheral neuropathy is, however, more common than 
central nervous system involvement. 
In patients with WG has been documented a high incidence of venous thrombotic events 
(VTEs). According to WeCLOT study (27) the incidence of VTEs was 7/100 person-years, but 
rotine anticoagulation for all patients is not recommended. Antiplasminogen antibodies 
were higher in PR3-ANCA patients than healthy control subjects (five in nine patients with 
VTE were positive for antiplasminogen antibodies) (28). 
Less frequently, involvement of the heart (present in 6-44% of the patients with pericarditis, 
myocarditis, conduction system abnormalities and coronary vasculitis) (29); gastrointestinal 
tract (splanchnic vasculitis, abdominal pain); oral cavity (“strawberry gingival 
hyperplasia”); lower genitourinary tract (urethra, ureters, cervix, vagina, testicular and 
prostate), parotid glands, thyroid gland (hyperthyroidism), liver or breast is seen. 
 
Organ 
involvement 
Percent at initially of the 
disease 
Percent during the course of 
disease 
ENT 73 92 
Lung 45 85 
Kidney 18 77 
Ocular 15 52 
Skin lesions 13 46 
Table 1. Percent of organ involvement in WG (22) 
5. Laboratory findings 
Characteristic laboratory findings are nonspecific and include elevated sedimentation rate and 
C-reactive protein, mild normocitic, normochromic anemia (50%), leukocytosis with neutrophil 
predominance, thrombocytosis (>400,000/microL) as an acute phase reactant, elevated blood 
urea nitrogen and creatinine levels, hypoalbuminemia, hypergammaglobulinemia (essentially 
of the IgA class), antinuclear antibody may be positive and slightly elevated rheumatoid factor 
levels. Patients should have a urinalysis, including microscopic analysis of urinary sediment, to 
determine the presence of hematuria and proteinuria. 
Almost 90% of the patients with active WG have a positive anti-PR3 ANCA and only a small 
percentage of patients may have anti-myeloperoxidase (anti-MPO) ANCA. 
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ANCAs can be detected by two methods: immunofluorescence (IF) and enzyme-linked 
immunosorbent assay (ELISA). The former is a qualitative ANCA assay and there are three 
IF patterns recognized: cytoplasmic (C-ANCA), perinuclear (P-ANCA) and atypical. 
However, this technique has significant inter-reader variability unlike ELISA. The latter 
provides target antigen-specific characterization of ANCA. Only ANCA directed against 
PR3 or MPO have been associated with primary vasculitic syndromes. False positive ANCA 
titers appear in certain infectious and neoplastic diseases. Together, IF and ELISA confer 
96% of sensitivity and 98,5% of specificity for the diagnosis of WG (30).  
C-ANCA directed against PR3 is most specific for WG, especially if active 
glomerulonephritis is present. Rising C-ANCA titers may herald a relapse in some patients 
with WG, but this relationship is unreliable (31). 
The measurement of PR3 membrane expression on neutrophils by flow cytometry (an 
increase is predictive of relapse) is a promissory marker for the activation of WG, but more 
research is needed (30). 
6. Diagnosis 
In a patient with the clinical features described above, the diagnosis of WG requires the 
demonstration of necrotizing granulomatous vasculitis on tissue biopsy, often from a site of 
active disease, being lung and kidney biopsies the most specific (lung biopsy is performed 
in the absence of renal involvement).  
WG can be classified according to the nomenclature of the Chapel Hill Consensus (CHC) 
Conference for primary systemic vasculitis (table 2) (32) and according to the classification 
criteria defined by the American College of Rheumatology (ACR) (table 3) in 1990 (33). 
 
- Granulomatous inflammation involving the respiratory tract and 
- Necrotizing vasculitis affecting small- to medium-sized vessels (capillaries, venules, 
arterioles and arteries)  
- Necrotizing glomerulonephritis is common 
- Cytoplasmic pattern ANCAs (C-ANCA) with antigen specificity for proteinase 3 (PR3) 
are a very sensitive marker for WG 
Table 2. Definition of WG according to the Chapel Hill Consensus Conference 
 
1. Nasal or oral inflammation: oral ulcers or purulent or bloody nasal discharge 
2. Abnormal chest radiograph: nodules, fixed infiltrates or cavities 
3. Nephritic urinary sediment: microhematuria or red blood cells casts 
4. Granulomatous inflammation on biopsy 
5. For the diagnosis of WG the patient must have, at least, 2 or more of these 4 criteria 
(sensitivity of 88,2% and specificity of 92%) 
Table 3. American College of Rheumatology Classification Criteria 
The European Vasculitis Study Group (EUVAS) has developed a definition of the disease 
stage including localized disease (table 4) (34). WG can also be divided in limited (absence of 
disease features that pose immediate threats to either a critical individual organ or to the 
patient’s life) or severe disease. 
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Disease Stages Organ involvement Detection of ANCA 
Localized Upper and lower airways - / + 
Early systemic 
Any, but no imminent organ failure, 
creatinine < 150µmol/L 
+ 
Generalized Any, creatinine < 500µmol/L + 
Rapid progressive GN Creatinine > 500µmol/L + 
Refractory Progress in spite of therapy + 
Table 4. Disease stages according to the European Vasculitis Study Group (EUVAS) 
7. Differential diagnosis 
The differential diagnosis includes pathologies with related clinical features, mainly lung - 
kidney syndrome, or with similar laboratory findings (ANCA positive). The following table 
lists the most relevant disorders (table 5). 
 
Churg - Strauss Syndrome NK nasal type lymphoma 
Microscopic polyangiitis Cocain induced 
Goodpasture’s syndrome Lymphomatoid granulomatosis (EBV) 
Relapsing polycondhritis Hemolytic- Uraemic syndrome 
Upper airways or lung tumors Infective endocarditis 
Glomerulonephritis Polyarteritis nodosa 
Histoplasmosis Sarcoidosis 
Rhinoscleroma Systemic Lupus Erythematosus 
Table 5. WG´s differential diagnosis 
8. Treatment 
Therapy is adapted according to disease stage and activity (35) and requires remission 
induction with initial immunosuppressive therapy, followed by maintenance 
immunosuppressive therapy to prevent relapse and control the disease. 
8.1 Remission induction 
Patients with limited disease (localized/early systemic) should be treated with oral steroids 
1mg/Kg/day in combination with oral or subcutaneous methotrexate (20-25mg/week), 
according to the NORAM study (36). Daily folic acid 1mg/day is recommended. In these 
cases cyclophosphamide should be avoided due to associated toxicity. Methotrexate is equal 
to cyclophosphamide in inducing remisson (36), although the former was associated with 
more relapses at 18 months, compared to cyclophosphamide, 69,5% vs 46,5% , respectively. 
Patients with generalized disease or severe disease (threatened vital organ function) should 
be treated with cyclophosphamide in combination with steroids (FAUCI scheme, introduced 
in 1970s). 
Cyclophosphamide can be given orally (2mg/Kg/day and the maximum dosage is 
200mg/day) or intravenously (15mg/Kg every 2 weeks for the first 3 pulses, then every 3 
weeks for the next 3-6 pulses, being the maximum dose 1500mg) and must be adjusted to 
renal function and age (table 6). The total duration of treatment should not exceed 6 months 
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(37). Pulsed cyclophosphamide has fewer side effects (lower rate of leucopenia) than oral 
doses, with equal efficacy (38) for remission induction. However, higher relapse rates in the 
maintenance phase, following the pulsed scheme, have been reported, and more studies are 
needed to assess this (35). 
 
Age (years) Creatinine 150-300µmol/l Creatinine 300-500µmol/l 
< 60 
> 60 and <70 
>70 
15mg/Kg/pulse
12,5mg/Kg/pulse 
10mg/Kg/pulse
12,5mg/Kg/pulse 
10mg/Kg/pulse 
7.5mg/Kg/pulse 
Table 6. Pulsed cyclophosphamide reductions for renal function and age 
Steroids were always considered the cornerstone of therapy. Although their use has not 
been evaluated in randomized controlled trials, every clinical trial has used this therapy in 
combination with another immunosuppressant. The ideal dose and duration of steroid 
therapy is unknown and further studies are needed. They are usually given orally 
(1mg/Kg/day of prednisolone during 1 month and then tapering slowly), but in the set of 
rapidly progressive glomerulonephritis and/or alveolar hemorrhage intravenous pulse 
methylprednisolone (0,5-1g/day for 3 consecutive days) can be used. In these two settings, 
plasma exchange can also be considered as adjuvant, although it has not been shown to 
improve overall survival. 
Patients treated with cyclophosphamide and corticosteroids should receive prophylaxis 
against Pneumocystis jiroveci pneumonia with trimethoprim/sulfamethoxazole 960mg 3 
times per week or, in cases with allergy to this antibiotic, dapsone 100mg daily.  
8.2 Remission maintenance 
In order to minimize exposure to the side effects of treatment with cyclophosphamide, 
alternative therapies have been proposed in recent years. 
In the remission maintenance three agents can be used: azathioprine (2mg/Kg/day), 
methotrexate (20-25mg/week) and leflunomide. According to the CYCAZAREM trial (40), 
the former is safer than and as effective as cyclophosphamide. In a trial published in New 
England Journal of Medicine in December 2008, methotrexate has been shown to be similar 
to azathioprine in security and efficacy in maintaining remission (41). Leflunomide was 
compared with methotrexate in a small trial and the results showed a trend to lower relapse 
rates with the first agent, but with more adverse effects (42). In this study the dose of 
leflunomide was 30mg/day. 
Mycophenolate mofetil (2g/day) can also be considered for maintenance therapy when 
there is intolerance or lack of efficacy with azathioprine or methotrexate, although more 
studies are needed. 
8.3 Alternative therapies 
Alternative therapies have increasingly been investigated, some of them with promise results. 
Several studies showed clinical improvement or remission with rituximab (375mg/m2 per 
week for four weeks). This data was confirmed by two recent trials, RAVE (43) and 
RITUXVAS (44), which showed non inferiority of rituximab compared with 
cyclophosphamide for induction of remission for the first study and remission of severe 
disease (renal involvement) for the second trial, with the former study reporting a possible 
superiority of rituximab in relapsing disease and in the RITUXVAS trial the rituximab group 
was associated with high rate of severe adverse events. 
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Etanercept studies, namely the Wegener´s granulomatosis etanercept (WGET) trial (45) didn´t 
find improvement in the maintenance of remission, with either severe or nonlifethreatening 
disease activity, when added to standard therapy, with a possible risk to increase infections 
and malignancies. This study didn´t evaluated this drug per se. 
Infliximab, antithymocyte globulins and alentuzumab (CAMPATH-1H study) (46) are under 
investigation and further studies are needed to define their role in therapy. 
Some studies suggest the use of intravenous immunoglobulin for refractory vasculitis, when 
conventional therapy is contra-indicated or for relapsed disease. However more studies are 
needed.  
9. Prognosis 
Patients with WG should have a closely follow-up, with regularly visits to her/his physician, 
involving multidisciplinary approach, and frequents exams to monitored the disease.  
Relapse is common (50% within 5 years), being ANCA status at diagnosis, target organ 
involvement (lung, renal, heart and chronic nasal carriage of Staphylococcus aureus) and 
treatment with <10g of cyclophosphamide in the first 6 months, maintaining prednisone 
>20mg/day for <2, 75 months and/or goal of zero dose of glucocorticoids factors associated 
to high risk of relapse (47). 
Untreated generalized or severe disease has a poorer prognosis, with a mortality rate up to 
90% within 2 years, but the introduction of immunosuppressive therapy increases the 
lifelong of these patients, being the overall 10-year survival rate 75-88% (48). Renal 
involvement is associated with a bad prognosis. 
The leading causes of death are infection, respiratory and renal failure, malignancy and 
cardiovascular disease, being the first one the major responsible for the mortality and 
morbidity in WG. 
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Braz Nogueira (2011). Wegener’s Granulomatosis, Advances in the Etiology, Pathogenesis and Pathology of
Vasculitis, Dr. Luis M Amezcua-Guerra (Ed.), ISBN: 978-953-307-651-5, InTech, Available from:
http://www.intechopen.com/books/advances-in-the-etiology-pathogenesis-and-pathology-of-
vasculitis/wegener-s-granulomatosis
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
